TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
  • March 8, 2021

SILVER SPRING, MD—The FDA granted conditional approval of Laverdia-CA1 (verdinexor) tablets as a treatment for dogs with lymphoma. The drug prevents certain proteins from leaving the nucleus of cancer cells, allowing these proteins to control the growth and prevent the spread of cancerous cells in dogs. It is the first conditionally approved oral treatment for dogs with lymphoma. The product is manufactured by Anivive Lifesciences, Long Beach, CA.